News · 26 weeks52+360%
2025-12-282026-06-21
Mix4290d
- SEC Filings19(45%)
- Insider18(43%)
- Other4(10%)
- Leadership1(2%)
Latest news
25 items- INSIDERNew insider Takeover Time 2026 Llc claimed ownership of 3,420,439 shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERLarge owner Hrt Financial Lp sold $40,722 worth of Class A Shares (3,132,480 units at $0.01), closing all direct ownership in the company (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERLarge owner Drw Securities, Llc sold $1,001 worth of shares (126,772 units at $0.01), closing all direct ownership in the company (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERLarge owner Hrt Financial Lp decreased direct ownership by 86% to 344,964 units (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERNew insider Drw Securities, Llc claimed ownership of 126,772 shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Aditxt Inc.SCHEDULE 13G - Aditxt, Inc. (0001726711) (Subject)
- INSIDERLarge owner Hrt Financial Lp bought $68,044 worth of shares (4,252,767 units at $0.02) (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERLarge owner Bank Of America Corp /De/ bought $0 worth of shares (7 units at $0.01) and sold $0 worth of shares (15 units at $0.01) (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERNew insider Bank Of America Corp /De/ claimed ownership of 57 shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERLarge owner Hrt Financial Lp sold $39,668 worth of shares (2,833,463 units at $0.01), closing all direct ownership in the company (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERLarge owner Hrt Financial Lp bought $83,532 worth of shares (2,148,823 units at $0.04) and sold $28,996 worth of shares (878,659 units at $0.03) (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERLarge owner Gong Sandie sold $6,880 worth of shares (100,000 units at $0.07) (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERNew insider Gong Sandie claimed ownership of 100,000 shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- SECAditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- INSIDERNew insider Hrt Financial Lp claimed ownership of 1,193,333 shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- SECAditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 MillionTransaction values Ignite Proteomics at approximately $150 million and is expected to position Ignite as an independent NYSE-listed functional proteomics company, while Aditxt continues as a separate Nasdaq-listed company Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt"), a qualified acquisition corp and Ignite Proteomics, LLC ("Ignite", or "Ignite Proteomics"), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement. The transaction values Ignite at an implied equity value of approximately $150 million, subject to the terms and conditions of the business combination agreem
- INSIDERLarge owner Hrt Financial Lp bought $64,115 worth of shares (843,622 units at $0.08) and sold $45,599 worth of shares (735,462 units at $0.06) (SEC Form 4)4 - Aditxt, Inc. (0001726711) (Issuer)
- INSIDERNew insider Hrt Financial Lp claimed ownership of 505,302 shares (SEC Form 3)3 - Aditxt, Inc. (0001726711) (Issuer)
- PRIgnite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy SelectionRegistry expected to pair Ignite's reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for Ignite over the course of the agreement Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics") a subsidiary of Aditxt, Inc. (NASDAQ:ADTX), today announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite's CLIA-certified Reverse Phase Protein Array ("RPPA") platform with structured clinical outcomes tracking to evaluate the real-world utility of functional proteomics in cancer therapy selection. The initiative is expected to
- SECAditxt Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECAditxt Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- PRAditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to ShareholdersSeasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven growth. Aditxt, Inc. (NASDAQ:ADTX)("Aditxt" or the "Company"), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision on
- SECAditxt Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Aditxt, Inc. (0001726711) (Filer)
- SECSEC Form PRE 14A filed by Aditxt Inc.PRE 14A - Aditxt, Inc. (0001726711) (Filer)
ADTX FAQ
6 questionsWhat does Aditxt Inc. do?
ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin...Where does ADTX stock trade?
Aditxt Inc. (ADTX) is listed on NASDAQ.What sector and industry is ADTX in?
Aditxt Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aditxt Inc. go public?
Aditxt Inc. (ADTX) completed its IPO in 2020.What companies are similar to ADTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ADTX side-by-side with any of them on Quantisnow.How can I track ADTX on Quantisnow?
Quantisnow aggregates Aditxt Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADTX to receive live email and push alerts on every new disclosure.